Quest Diagnostics raised its full-year revenue and earnings forecasts after reporting a 10% increase in third-quarter revenue to $3.097 billion. Reported diluted earnings per share rose to $2.78 from $2.16, while adjusted diluted EPS reached $3.00. The 22 October 2026 announcement also needs to be read alongside a separate filing about unauthorized access to one of its systems.
The accounts cover the quarter ended 30 September 2026. All amounts are US dollars. Adjusted figures exclude specified items and do not replace the reported accounting result.
What the quarterly accounts show
| Measure | Q3 2026 | Q3 2025 | Official evidence |
|---|---|---|---|
| Revenue | $3.097 billion | $2.816 billion | Issuer source |
| Net income attributable to Quest, reported | $312 million | $245 million | Issuer source |
| Diluted EPS, reported | $2.78 | $2.16 | Issuer source |
| Diluted EPS, adjusted/non-GAAP | $3.00 | $2.60 | Issuer source |
| Cash provided by operations | $611 million | $563 million | Issuer source |
Quest’s adjusted EPS excludes items including amortization, restructuring and integration costs, certain investment changes and excess tax benefits linked to share-based compensation. The reconciliation adds some expenses back but also removes some gains and benefits. It is therefore a defined alternative measure, not a claim that every excluded cost is irrelevant.
Higher guidance remains a forecast
Quest now expects 2026 revenue of $12.065 billion to $12.105 billion, compared with its previous $11.95 billion to $12.05 billion range. It forecasts reported diluted EPS of $10.21 to $10.31 and adjusted diluted EPS of $11.25 to $11.35. Previously those EPS ranges were $9.97 to $10.17 and $11.05 to $11.25 respectively.
The annual numbers are management estimates, not earnings already delivered. The company identifies demand, reimbursement, competition, integration and other operating risks, and says future special items may still affect reported earnings. Its revenue-growth statement should not be converted into a prediction of the share price.
A separate investigation is still open
In its 22 October SEC filing, Quest said it learned on 21 October of unauthorized access to its Quanum LSM system, which certain clients use for test orders and results. It said it believed an unauthorized party had accessed certain patient records, while the full scope remained under investigation.
The company said the incident had not materially disrupted business operations or its ability to serve patients as of the filing. That statement does not establish that the investigation is complete or that there will be no future expense, liability or other effect. This report does not disclose patient information or infer the number of people affected.
For a comparison of accounting and alternative earnings measures, see CapKet’s Thermo Fisher earnings report. Company-specific definitions and risks still matter when comparing results.
Official sources and verification
Official announcement (observed 2026-10-22T19:45:41.267Z); Issuer results/news index (observed 2026-10-22T19:47:06.128Z); Official SEC filing (observed 2026-10-22T19:48:05.264Z). An issuer index confirms publication availability, not independent corroboration of the figures. Material amounts and qualifications were checked in the linked primary documents. This is AI-assisted primary-document review, not independent human editorial approval. Information only, not investment advice.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.